Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Media

ASX trades sideways, but this immuno-oncology company is up 9.1%

Australian stocks traded sideways today with the ASX200 putting on just 2.4 points. Find out which immuno-oncology company has empirical research demonstrating promising inhibition of tumour cells by its peptide vaccine.

Australian stocks failed to build on yesterday’s gain with the ASX200 closing nearly unchanged with a 2.4 point gain to 5,664.7.

Energy stocks were amongst the biggest gainers with the Energy Index rising 1.9% to 11,603.6 points.

Oil Search (ASX:OSH) rose 2.4% to $7.57, Santos (ASX:STO) gained 2.3% to $8.09 and Woodside Petroleum (ASX:WPL) climbed 1.5% to $34.84.

Market Action here…

Imugene Limited (ASX:IMU) drew investors with its shares climbing 9.1% to $0.012 with almost 107.9 million shares traded.

This follows its research that demonstrated promising inhibition of tumour cells by its Her-Vaxx peptide vaccine for HER-2 positive gastric and breast cancer compared with Roche’s Herceptin drug in tumour model.

In empirical work, pre-clinical data showed that a higher dose of HER-Vaxx is able to inhibit cancer cell growth 70% greater than Herceptin.

While clinical trials are required to confirm this, the result is promising given that Herceptin generated annualised sales of $6.9 billion.

The Phase 1b/2 clinical trial remains on track to begin in the second half of 2015.

Phase 1b is designed to confirm low toxicity and select the optimal dose from three different doses of HER-Vaxx while Phase 2 will use the dose identified in Phase 1b and assess clinical efficacy of HER-Vaxx in two groups of 34 patients in a placebo-controlled trial design.

This trial will improve understand of HER-Vaxx’s functioning from an early stage including showing the increased modulation of the immune system and demonstrating again the production of HER-2 antibodies by patients’ immune systems

Adding interest, the trial will use a re-formulation of Her-Vaxx that shows more rapid and greater anti-cancer antibody production.

Redflow (ASX:RFX) is up 12.8% to $0.265, Charter Pacific (ASX:CHF) jumped 55.6% to $0.042, Argonaut Resources (ASX:ARE) climbed 16.7% to $0.007 while Legend Mining (ASX:LEG) is up 14.3% to $0.008 with almost 4 million shares traded.

Metals of Africa (ASX:MTA) rose 10.8% to $0.072, Phoenix Copper (ASX:PNX) climbed 16.7% to $0.021 and Botswana Metals (ASX:BML) is up 16.7% to $0.007 with about 1.3 million shares traded.

Blue Chip Stocks

Major Miners

BHP Billiton (ASX:BHP) crept up 0.03% to $29.25

Fortescue Metals Group (ASX:FMG) fell 0.5% to $2.11

Newcrest (ASX:NCM) rose 2.3% to $14.31

Rio Tinto (ASX:RIO) slipped 0.3% to $56.75

Big 4 banks

ANZ Bank (ASX:ANZ) dropped 0.5% to $32.05

Commonwealth Bank (ASX:CBA) fell 0.5% to $83.11

National Australia Bank (ASX:NAB) is down 0.5% to $33.23

Westpac (ASX:WBC) down 0.3% to $32.56

Other banks, financials and industrials

AMP (ASX:AMP) fell 0.6% to $6.40

Bank of Queensland (ASX:BOQ) up 0.3% to $13.05

Bendigo and Adelaide Bank (ASX:BEN) rose 0.6% to $12.16

Macquarie Group (ASX:MQG) dipped 0.1% to $79.64

Suncorp (ASX:SUN) up 0.2% to $13.12

Telstra (ASX:TLS) up 0.3% to $6.20

Retailers

JB Hi-FI (ASX:JBH) dropped 0.8% to $21.18

Wesfarmers (ASX:WES) slipped 0.1% to $43.33

Woolworths (ASX:WOW) down 0.6% to $28.18

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK